Board of Directors
Our Board of Directors brings together seasoned leaders with extensive experience across clinical development, life sciences, and global business. Their diverse perspectives and strategic guidance help shape Novotech’s vision and growth, ensuring we remain a trusted partner in accelerating clinical research across the globe. Through strong governance and a commitment to innovation, integrity, and scientific excellence, our Board supports Novotech’s mission to enhance patient outcomes by accelerating the development of new treatments and therapies.
Board of Directors
Dr. Anand Kumaresh Tharmaratnam
Dr. Tharmaratnam is Novotech’s Chief Executive Officer and Chairman, bringing more than 30 years of experience across the global CRO and life sciences industry. He has served on the Novotech Board since 2021 and has been closely involved in guiding the company’s strategic direction and growth. A UK-trained physician specializing in anesthesia and critical care, Anand previously spent 23 years at Quintiles and its successor organization, IQVIA, including 10 years on their global executive committees as Head of Asia and Japan. As CEO and Chairman, he is leading Novotech into its next phase of global expansion, strengthening scientific capabilities, and delivering high-quality outcomes for biotech clients worldwide.
Joel Thickins
Joel Thickins is a Partner and the Co-Head of Asia at TPG, co-Managing Partner for TPG Capital Asia, and the Managing Partner of TPG Emerging Companies Asia (TĒCA). He is the current Chairman of Greencross Limited, Australia and New Zealand’s largest pet wellness and vets platform, and InvoCare, a leading provider of funeral, cemetery, and crematoria services in Australia, New Zealand, and Singapore, and the Deputy Chairman of Novotech, a globally recognized full-service biotech specialist clinical research organization. Previously, Mr. Thickins served as Chairman at iNova Pharmaceuticals, a leading independent consumer healthcare and medicine products company, Made Group, one of Australia’s largest healthy food and beverage businesses, and Funlab, Australia’s premier creator of competitive socialising experiences. He is also a former Director of Ingham’s and Accolade Wines.
TAN Hwee Loo
TAN is a Non-Executive Director of Novotech and Head of Asia within the Private Equity department at GIC, where she oversees investments across China, India, Southeast Asia, Japan, Korea, and Australia/New Zealand. She joined GIC in 2001 and has held a range of senior leadership roles across global investment strategy and private equity investing, including appointments in London and Singapore. Her experience spans economic research, private equity fund investment, secondaries, co-investments, direct investments and global strategy and risk. Within GIC, she serves on the Human Resource Committee and the Resilience Fund panel, and externally she is a member of the Investment Committee of the Singapore University of Social Sciences.
Vincent Wong
Vincent Wong is a Firm Partner with TPG Capital and Co-Head of Healthcare for TPG Asia and is based in Melbourne, where he works in TPG’s Australian team. Prior to joining TPG in 2011, Vincent served in the corporate advisory division at Goldman Sachs Australia. Vincent graduated from the University of Melbourne with BCommerce and BLaws (Honors).
Korwin Chiu
Korwin is a Senior Vice President at GIC, where he oversees healthcare private equity investments across the Asia-Pacific region. He brings more than 15 years of experience investing in the healthcare sector. Prior to joining GIC in 2012, he held roles at Court Square Capital in New York and Bank of America.
Ethan Park Jung Ryun
Ethan is a Managing Director at Temasek, where he leads healthcare and life sciences investment activities across Europe, the Middle East and Africa (EMEA), and Southeast Asia (SEA). Prior to Temasek, he held roles at SK Corporation in Seoul, Korea. He serves on the boards of several healthcare and life sciences companies.
Zubin Jamshed Irani
Zubin is Partner and Head of Operations for TPG in Asia, where he is responsible for the performance of TPG’s portfolio across Asia Pacific. He brings over 27 years' experience in building strong teams, driving performance, and managing change within businesses. For the last 10 years, Zubin has built TPG’s value creation capability and operations team in Asia. He has worked across the consumer, healthcare, financial services, technology and industrial sectors. Zubin works closely with the management teams in TPG’s portfolio companies, guiding the execution of the value creation plan and driving performance improvement. He has also been an Exco/Board member for several TPG portfolio companies in Asia over the past few years.
Elaine June Cheung
Elaine has over 30 years of experience as a global CFO and Board Director across healthcare, consumer goods, and education. Her leadership roles include Dole, Temasek, VF Corporation, and Zuellig Pharma. She serves on multiple global boards and is a respected Audit Committee Chair, providing strong governance and financial oversight.
Dr. Fred Ehrenkranz Cohen
Dr. Cohen is a Senior Advisor to TPG where he was a Partner and co-founder of TPG Biotech. He currently serves as the Chairman of Monograph Capital Partners, a life sciences venture capital group. Prior to TPG, Dr. Cohen was a Professor of Medicine and Pharmacology at UCSF. He has extensive experience in biotechnology investing and governance, and has served on the boards of multiple biotechnology and pharmaceutical companies, including Quintiles Transnational (NYSE: Q), Progyny (NASDAQ: PGNY), Aptalis and BioCryst Pharmaceuticals (NASDAQ: BCRX). He currently serves on the boards of CareDx (NASDAQ: CDNA), Intellia (NASDAQ: NTLA) and Kyverna Therapeutics (NASDAQ: KVTX)
Executive Leadership Team
Novotech’s leadership combines deep expertise with a strong commitment to advancing clinical research. Unlike many clinical research organizations with centralized leadership, our senior leaders are based across North America, Asia-Pacific, and Europe, ensuring accessibility, engagement, and regional expertise.
Senior Management
Dr. Anand Kumaresh Tharmaratnam
Dr. Tharmaratnam is Novotech’s Chief Executive Officer and Chairman, bringing more than 30 years of experience across the global CRO and life sciences industry. He has served on the Novotech Board since 2021 and has been closely involved in guiding the company’s strategic direction and growth. A UK-trained physician specializing in anesthesia and critical care, Anand previously spent 23 years at Quintiles and its successor organization, IQVIA, including 10 years on their global executive committees as Head of Asia and Japan. As CEO and Chairman, he is leading Novotech into its next phase of global expansion, strengthening scientific capabilities, and delivering high-quality outcomes for biotech clients worldwide.
Vivek Kapoor
Vivek is Novotech’s Chief Financial Officer, responsible for financial planning and controls, and overseeing Corporate Finance, Accounting, Procurement, Real Estate, Shared Services, Investor Relations, and IT Infrastructure. He is a senior finance leader with more than 30 years of experience across life sciences, healthcare, and technology in Asia Pacific, Japan, the Middle East, and Africa. Prior to Novotech, Vivek served as CFO AMEA at Guardant Health and CFO for Asia Pacific at IQVIA, where he supported significant growth, acquisitions, and digital transformation.
Michael Stibilj
Michael is Novotech’s Chief Operations Officer, overseeing Global Clinical Services across Asia Pacific, Europe, the US, and Japan, as well as Global Project Management, Global Biometrics, Operational Strategy Leads, and Operational Medical Services. Michael has more than 25 years of experience in the CRO industry. Prior to joining Novotech in 2017, he spent 15 years building and leading operations across Asia for Quintiles/IQVIA and served as a Senior Advisor to TPG Capital, driving transformational growth and scalable global delivery.
Tim Bray
Tim is Novotech’s Chief Human Resources Officer, leading the company’s people and culture strategy and shaping how Novotech attracts, engages, and retains talent globally. He oversees Human Resource Management and is strengthening Talent Acquisition, Organizational Development, and Learning & Development. Tim brings deep global HR leadership experience across the life sciences and CRO sectors, having held senior roles at Quintiles/IQVIA, Bayer, and Novartis. He has led large-scale workforce growth, talent transformation, and leadership development across the Americas, EMEA, and Asia-Pacific markets.
Dr. Judith Ng-Cashin
Dr. Ng-Cashin is Novotech’s Chief Medical Officer (CMO), leading the company’s Therapeutic & Scientific Strategy, Quality Assurance, and Drug Development Consulting functions. She joined Novotech in 2023, bringing more than 20 years of international experience across pharmaceutical, biotech, and CRO environments. Based in the United States, Judith provides strategic medical leadership across global programs and multi-regional trials, ensuring scientific integrity and high-quality delivery for clients and patients. She has held senior executive roles at Syneos Health, INC Research, Quintiles, Eagle Pharmaceuticals, AoBiome, and GlaxoSmithKline.
Prashant Dhami
Prashant is Novotech’s Chief Strategy Officer, responsible for Corporate Strategy and Development, Mergers & Acquisitions, and value creation initiatives. He also oversees Marketing and Communications and supports the launch of new offerings and customer segments. Prashant brings extensive experience in strategy, commercial leadership, and healthcare advisory, having held senior roles at IQVIA across Asia Pacific, including P&L leadership of consulting, real-world evidence, and commercial services businesses. He is also a Senior Advisor to TPG, providing strategy and value creation support across its healthcare portfolio.
Barry Murphy
Barry is Novotech’s Chief Commercial Officer (CCO), leading Business Development and Sales Operations across all markets, including Global Sales Operations and Key Account Management. He joined Novotech in 2014 and has played a key role in scaling the company’s commercial capabilities, expanding its sales focus from emerging biotech to established biotech and mid-sized pharmaceutical companies. Barry began his career as a pharmacist and brings deep CRO industry experience, having previously held multiple contract management roles at ICON plc.
Andy Liu
Andy is Novotech’s Managing Director, Greater China and Global Labs, responsible for managing and growing the company’s regional business across Mainland China, Taiwan, and Hong Kong, as well as leading global laboratory services. Based in Shanghai, Andy brings more than a decade of CRO industry experience, having held multiple senior leadership roles at Covance, including General Manager of Central Laboratory Services for Asia Pacific, where he led large, multi-functional teams across multiple sites and drove regional operational growth.
Dr. Yooni Kim
Dr. Kim is Novotech’s Chief Customer Experience Officer (CXO), dedicated to enhancing the global customer experience and strategically transforming service offerings into core products with a focus on inbound growth in the JAPAC region and large strategic opportunities. She ensures customer-centricity is embedded across Novotech’s service delivery and solutions. She brings more than 25 years of clinical research experience across CRO, pharmaceutical, and academic settings – including operational leadership roles in GSK and ICON - she joined Novotech in 2016. Having previously served as Managing Director of Asia Pacific and Vice President of Clinical Services, she now leads Novotech’s global service productization and customer experience management.
Our Global Leaders
Novotech’s global and regional leadership team brings together diverse expertise and on-the-ground insight to deliver operational excellence across every market we serve. With leaders embedded in key regions worldwide, our structure enables agile decision-making, seamless collaboration, and consistent delivery of high-quality clinical research outcomes for our partners.
Dr. Daniela Caiazza
Daniela is an experienced executive leader with over 20 years Life Sciences experience in clinical research organizations, pharmaceutical companies, and academic institutions. Daniela has strong expertise in clinical development, P&L and financial management, strategy, quality and compliance management and people leadership across global regions. She is passionate about mentoring, advocacy and forging industry and academic collaborations to promote efficiencies and enhance capabilities for the clinical trial sector. Daniela holds a PhD in Chemistry from Adelaide University and is a Board Member and Deputy Chair for ARCS Australia.
Scott Davis
Scott oversees Clinical Services across Europe including Clinical Operations, Regulatory, Feasibility and contracting. He has more than 30 Years experience in clinical drug development across Biotech, Pharma and CROs. Prior to Joining Novotech in 2026 he was the Global Head of Early Clinical Development and EMEA Head of Therapeutic Strategy for IQVIA. Scott has also been a strategic Clinical Development Consultant for a number of MedTech, Private Equity and Healthcare companies such as Apple where he was a Strategic Health Consultant.
Rachael Fraizer
Rachael supports our global commercial organization through disciplined execution, data-driven sales operations, and scalable enablement, aligned to Novotech’s biotech-first partnership model. With over 15 years of experience across global CRO environments, she specializes in building scalable commercial infrastructure, optimizing execution, and enabling high-performing teams. Her leadership philosophy reflects our collaborative, high-touch approach: creating clarity, accountability, and operational foundations enabling teams to deliver with speed, quality, and confidence. She is passionate about empowering teams to focus on what matters most, advancing innovative therapies that improve patient lives globally.
Martin Guan
Martin is responsible for driving the execution of the global laboratory development strategy. In this role, he focuses on enhancing operational efficiency and quality standards while orchestrating coordination and management across regional laboratories. Martin brings extensive international experience and proven commercial expertise from the global laboratory sector, leveraging his background to deliver scalable growth and operational excellence.
Elaina Haeuber
Elaina is a senior biopharmaceutical executive with over 20 years’ experience across biotechnology, pharmaceutical, and CROs. She has led global clinical development, operations, and strategic growth initiatives, most recently serving as Senior VP of Oncology with responsibility for global oncology portfolios and complex multinational programs. Elaina brings deep expertise across all phases of drug development, including oncology, cell and gene therapies, and radiopharmaceuticals. She is recognized for building high-performing teams, advancing innovative trial models, and aligning strategy with execution to deliver meaningful outcomes for patients and partners.
Raymond Jia
Raymond leads the regional Clinical Services team, including Clinical Operations and Regulatory Start-up functions. He joined Novotech in 2017 and has since played a pivotal role in building and scaling the China Clinical Operations and Project Management teams and driving the growth of the SMO business. Raymond’s career began as a Clinical Research Associate (CRA) and he went on to hold multiple leadership roles in Clinical Operations at Parexel. He further broadened his expertise at IQVIA, gaining extensive experience in portfolio and key account management.
Susan Johnson
Susan’s expertise is in leading regional delivery, client engagement, and operational strategy. She joined Novotech in 2026 with more than 30 years of industry experience spanning biotech, pharma, and CRO environments, bringing a rare combination of operational rigor, commercial acumen, and people-centric leadership. Prior to Novotech, Susan held senior roles including Vice President of Clinical Operations at Syneos Health and Executive Director & Global Head of Women’s Health & Strategic Accounts. Susan is recognized for strengthening partnerships, elevating operational delivery, and guiding teams across complex global portfolios.
Aditya Kotta
Aditya brings over a decade of expertise to the clinical research industry, with a career spanning project management, operations, and business development within the CRO sector.
Since joining Novotech in 2018, he has served in several key leadership capacities, including Head of Business Development for the US and Europe and US Senior Director of Business Development. Before his tenure at Novotech, Aditya built a diverse foundation across clinical operations and project management. He holds a bachelor’s degree in biomedical engineering from The Johns Hopkins University and a master’s degree in medical sciences from Boston University School of Medicine.
Takeshi Mori
Takeshi is leading Novotech’s Clinical and Regulatory Operations in Japan, including overseeing clinical trial conduct and managing customers. He joined Novotech in January 2026 and started to build local capabilities, strengthen partnerships with biotech clients and is continuing to develop our organization in Japan building out team on the ground there. Takeshi began his career as a CRA and brings deep pharmaceutical and CRO industry experience gained from previous multiple management positions such as Head of Japan R&D Strategy and Planning, Executive Director, Project Leadership and Director of Clinical Project Management roles at IQVIA, Parexel and BMS.
Marina Mullins
Marina oversees Novotech’s full ECD infrastructure, leading the strategy and execution of programs that advance therapeutic assets from preclinical research through first-in-human studies, with the ultimate goal of supporting clinical proof of concept. Previously, Marina led Novotech’s global therapeutic strategy team, providing strategic oversight across Oncology, Infectious Disease, CNS, immune-mediated diseases, and ATMPs. Earlier in her career, she led pharmacy functions within a Phase I unit, including building and commissioning a GMP clean room and establishing the supporting quality system; she is a registered Pharmacist in Australia.
David Ng
David is responsible for data processing and analyses, with functional groups in Statistics, Programming, Data Management, and Centralized Monitoring. He joined Novotech in 2023, with prior experience in global management roles with a large global CRO as well as a China based CRO. In total, he has over 35 yrs of experience in various global roles in statistics and data management, as well as large account management. He also provides strategic and operational insight for sponsor’s clinical development strategy, assisting sponsors with study design, endpoint selection, and supporting sponsor interactions with regulatory agencies.
Dr. Xiaoming Zhang
Xiaoming leads Novotech’s business development strategy and commercial growth across the Asia-Pacific region. As Head of Business Development, APAC, she is responsible for strengthening strategic client relationships, driving new business opportunities, and supporting market expansion across key markets. She brings nearly 20 years of experience in the CRO industry and joined Novotech in 2017. Prior to joining Novotech, she held multiple commercial roles at IQVIA (formerly Quintiles), spanning business development, strategic account leadership, and sales leadership.